Thammasat University

tu.ac.th

Total trials

93

Active

15

Phase 3

7

Total enrollment

10,154

Read this sponsor's pipeline like an analyst.

Generate a written report: strategic focus, priority programs, pipeline shape, recent terminations and momentum, and the trials worth watching in the next 12 months.

~15-30 sec · cached for 24h

Pipeline matrix

Showing 7 of 7 active programs · click any cell for trials

InterventionEarly Phase 1Phase 1Phase 2Phase 3Phase 4N/ATotal
Normal saline3
Tranexamic Acid2
Dinalbuphine Sebacate1
melatonin1
Paracetamol2
Mirogabalin1
Pregabalin1

Next readouts

  • 2025-05-31
  • 2025-11-06
  • 2026-06
  • 2026-09

Top conditions

  • Osteoarthritis, Knee7
  • Knee Osteoarthritis6
  • Postoperative Pain5
  • Total Knee Arthroplasty4
  • COPD4
  • Osteoarthritis4
  • Asthma3
  • Allergic Rhinitis3

Frequently asked questions about Thammasat University

How many clinical trials does Thammasat University have on ClinicalTrials.gov?
Thammasat University is listed as the lead sponsor on 93 clinical trials in ClinicalTrials.gov, 15 of which are currently active (recruiting, enrolling, or ongoing).
How many of Thammasat University's trials are in Phase 3?
7 of Thammasat University's trials are in Phase 3, spread across 7 active drug programs.
What therapeutic areas does Thammasat University focus on?
Thammasat University's most-studied conditions on ClinicalTrials.gov are Osteoarthritis, Knee, Knee Osteoarthritis, Postoperative Pain, Total Knee Arthroplasty, COPD.
When are Thammasat University's next clinical trial readouts?
Thammasat University has 4 upcoming primary-completion readouts tracked here; the soonest is “Comparing Efficiency of Mirogabalin and Pregabalin in Primary TKA”, expected around 2025-05-31.